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1. Overview and Definition of Substance Abuse 
1.1 Overview 
It is clear that the misuse of licit and illicit substances has a profound effect in terms 
of harm across all areas of society.  This includes high costs in terms of healthcare 
provision, social and economic costs as well as the effect on individuals and their 
families. Problem substance use is increasing in Ireland, with one fifth of all 
individuals treated from problem substance abuse being aged 18 or under.   The 
majority of cases in Ireland result from use of cannabis or opiates, however the use 
of cocaine is increasing (Health Services Executive, 2008).  
Substance misuse can take the form of anti-social or harmful behaviour, and have 
harmful effects on the individual in terms of physical health (overdose, hepatitis, HIV, 
respiratory problems), mental health (depression, anxiety disorders, suicide), social 
problems and criminal and violence issues (DH, 2006; NCCHM, 2008).  
In the UK, the Advisory Council on the Misuse of Drugs (ACMD) describes drug 
misuse as a condition that may cause an individual to experience social, 
psychological, physical or legal problems related to intoxication and/or regular 
excessive consumption, and/or dependence (ACMD, 1998).  
Whilst consumption of any licit and illicit forms of drug can produce 
addictive/dependent behaviour (Nutt and Law, 2009), this protocol deals with illicit 
substances (opioids, cannabinoids,  sedative, anxiolytic and hypnotic drugs , 
crack/cocaine,  MDMA – Ecstasy, other stimulant drugs such as 
amphetamines, hallucinogens, volatile solvents and dissociative substances).   
The terms polydrug or polysubstance use are used to describe individuals who 
consume more than one of these substances.   
This protocol does not cover the abuse of licit substances (alcohol, tobacco or 
caffeine).  Please note conditions resulting from excess alcohol consumption are 
covered in a separate protocol Alcohol Related Disorders. 
The relative risks of substance abuse come not only from the risk of the drug itself, 
but from the extent that it controls an individual’s behaviour, the ease of stopping the 
drug, the risk of the route by which the drug is taken (for example the risk of 
contracting HIV or hepatitis from intravenous use) and from the social, economic 
and environmental considerations of drug use in terms of crime etc. 
1.2 Definition of the Condition 
Substance misuse or abuse is frequently classified as experimental, recreational, or 
dependant that may result in adverse physical and/or psychological effects (i.e. 
harmful use). This represents a wide-ranging spectrum of the use of therapeutic 
drugs or substances with physiological and psycho-active effects on the body or 
mind which are out with legal or medical guidelines. 
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Drug misuse is defined as the use of a substance for a purpose not consistent with 
legal or medical guidelines (WHO, 2006).   A further definition by the Royal College 
of Psychiatrists states “… any taking of a drug which harms or threatens to harm the 
physical or mental health or social well-being of an individual or other individuals or 
society at large, or which is illegal” (Royal College of Psychiatrists, 1987). 
Care should be taken when defining drug use in terms of addiction or dependence 
as these terms are not necessarily used with consistent meaning and also have 
social and cultural implications to their use.  Definitions are provided below from the 
two most recognised disease classification systems - the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders Fourth edition 
Text Revision (2000) – usually referred to as DSM-IV-TR - and the International 
Classification of Diseases (ICD-10) coding system published by the World Health 
Organisation (2007) in order to clearly describe the processes of substance abuse 
an dependence. 
1.3 Diagnostic and Statistical Manual of Mental Disorders 4th 
Edition Text Revision (DSM-IV-TR) Classification 
1.3.1 DSM-IV-TR Substance Abuse 
The term Substance Abuse is used when an individual will repeatedly consume an 
illicit substance but the pattern of this abuse does not lead to addiction or 
compulsive behaviour, nor withdrawal symptoms.  
DSM-IV-TR describes substance abuse as: a ‘maladaptive’ pattern of substance use 
leading to clinically significant impairment or distress, as manifested by one (or 
more) of the following within a 12 month period: 
1. Recurrent use leading to failure to fulfil major role obligations (work, 
home, school, etc.) 
2. Recurrent use in situations where it is physically hazardous (e.g. 
drunk driving) 
3. Repeated substance related legal problems (repeated disorderly 
conduct while drunk) 
4. Persistent use despite recurrent social/interpersonal problems 
caused or exacerbated by the effects of a substance (e.g. arguments 
with spouse or physical fights) 
Alternatively, the symptoms have never met the criteria for substance dependence 
for this class of substance. 
1.3.2 DSM- IV-TR Substance Dependence 
The term Substance Dependence is used when an individual compulsively and 
repetitively consumes an illicit drug despite problems related to the consumption of 
that drug, possible tolerance to the effects of the drug, and possible withdrawal 
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symptoms should the drug use be reduced or stopped altogether. 
DSM-IV-TR describes Substance dependence as a: ‘maladaptive pattern of 
substance use leading to clinically significant impairment or distress, as manifested 
by three (or more) of the following within a 12 month period: 
1. Tolerance: a need for increased amounts of a substance to achieve 
the desired effect or a diminished effect with ongoing use of the same 
amount of substance 
2. Withdrawal symptoms 
3. The substance taken in larger amounts over longer periods than was 
intended 
4. Persistent desire or unsuccessful efforts to cut down or control use 
5. A great deal of time spent in activities relating to obtaining the 
substance, using the substance or recovering from use 
6. Significant social, occupational or recreational activities are given up 
or reduced because of use 
7. Use continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused 
or exacerbated by the substance’ 
DSM-IV criteria for substance dependence include several specifiers, one of which 
outlines whether Substance dependence is: 
 With physiologic dependence (evidence of tolerance or withdrawal) or 
 Without physiologic dependence (no evidence of tolerance or 
withdrawal).  
In addition, remission categories are classified into four subtypes: (1) full, (2) early 
partial, (3) sustained, and (4) sustained partial; on the basis of whether any of the 
criteria for abuse or dependence have been met and over what time frame. The 
remission category can also be used for patients receiving agonist therapy (such as 
methadone maintenance) or for those living in a controlled, drug-free environment. 
(American Psychiatric Association, 2000) 
1.4 World Health Organisation: International Classification of 
Diseases 10th Edition (ICD-10) Classification 
ICD-10 classifies substance abuse mainly under the code F10-F19 Mental and 
behavioural disorders due to psychoactive substance use.  However, an 
additional code exists for non-dependence producing substances such as 
aspirin. 
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The codes in this range represent an individual diagnostic code for different 
substances. 
 F10  -  Mental and behavioural disorders due to use of alcohol 
 F11. – Mental and behavioural disorders due to use of opioids 
 F12. – Mental and behavioural disorders due to use of cannabinoids 
 F13. – Mental and behavioural disorders due to use of sedative hypnotics 
 F14. – Mental and behavioural disorders due to use of cocaine 
 F15. – Mental and behavioural disorders due to use of other stimulants, 
including caffeine 
 F16. – Mental and behavioural disorders due to use of hallucinogens 
 F17. – Mental and behavioural disorders due to use of tobacco 
 F18. – Mental and behavioural disorders due to use of volatile solvents 
 F19. – Mental and behavioural disorders due to multiple drug use and use of 
other psychoactive substances 
 F55 – abuse of non-dependence-producing substances (e.g laxatives or 
Aspirin) 
Further codes specify diagnostic criteria for the different clinical conditions (stages) 
that ICD-10 recognises as detailed below. 
1.4.1 Acute intoxication 
ICD-10 describes acute intoxication as a transient condition following the 
administration of alcohol or other psychoactive substance, resulting in disturbances 
in level of consciousness, cognition, perception, affect or behaviour, or other 
psycho-physiological functions and responses (WHO, 2007).  This diagnosis is not 
appropriate where harmful use or dependence exist, but covers conditions such as 
acute drunkenness in alcoholism and “bad trips” (due to hallucinogenic drugs). 
1.4.2 Harmful use 
ICD-10 describes harmful use as a pattern of psychoactive substance use that has 
caused the individual actual physical harm (as in cases of hepatitis from the self-
administration of injected drugs) or mental harm (e.g. episodes of depressive 
disorder secondary to heavy consumption of alcohol), but where dependent patterns 
of use do not exist. 
1.4.3 Dependence syndrome 
ICD-10 describes dependence syndrome as a cluster of physiological, behavioural, 
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and cognitive phenomena in which the use of a drug becomes a high priority for the 
user, overtaking other activities.  
A central descriptive characteristic of dependence syndrome is the desire (often 
strong, sometimes overpowering) to take psychoactive drugs (which may or may not 
have been medically prescribed), alcohol, or tobacco – the element of taking or 
desire to take in terms of dependence being the key; this diagnosis would not apply 
for example, so someone taking Opioid analgesics following major surgery even 
though an element of withdrawal may be present when such drugs are discontinued. 
There may be evidence that return to substance use after a period of abstinence 
leads to a more rapid reappearance of other features of the syndrome than occurs 
with nondependent individuals. 
Diagnostic guidelines 
A definite diagnosis of dependence should usually be made only if three or more of 
the following have been present together at some time during the previous year: 
(a) a strong desire or sense of compulsion to take the substance; 
(b) difficulties in controlling substance-taking behaviour in terms of its onset, 
termination, or levels of use; 
(c) a physiological withdrawal state (see F1x.3 and F1x.4) when substance 
use has ceased or been reduced, as evidenced by: the characteristic 
withdrawal syndrome for the substance; or use of the same (or a closely 
related) substance with the intention of relieving or avoiding withdrawal 
symptoms; 
(d) evidence of tolerance, such that increased doses of the psychoactive 
substances are required in order to achieve effects originally produced by 
lower doses (clear examples of this are found in alcohol- and opiate-
dependent individuals who may take daily doses sufficient to incapacitate or 
kill non-tolerant users); 
(e) progressive neglect of alternative pleasures or interests because of 
psychoactive substance use, increased amount of time necessary to obtain or 
take the substance or to recover from its effects; 
(f) persisting with substance use despite clear evidence of overtly harmful 
consequences, such as harm to the liver through excessive drinking, 
depressive mood states consequent to periods of heavy substance use, or 
drug-related impairment of cognitive functioning; efforts should be made to 
determine that the user was actually, or could be expected to be, aware of the 
nature and extent of the harm. 
1.4.4 Withdrawal State 
ICD-10 describes this state as being group of symptoms which may vary in nature 
and severity according to the dosage and type of substance which has been 
discontinued.  This may occur after repeated, and usually prolonged and/or high 
dose use of that substance. Onset and course of the withdrawal state are time-
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limited. Common psychological symptoms include anxiety, depression and sleep 
disorders.  A coded classification for withdrawal state with delirium also exists in 
this diagnostic classification system. 
1.4.5 Psychotic Disorder 
This occurs during or after substance use and will result in individuals experiencing 
vivid hallucinations, misidentifications, delusions, possibly paranoid type behaviours, 
psychomotor disturbances (excitement or stupor), and an abnormal affect, which 
may range from intense fear to ecstasy. The effects of this disorder resolve partially 
within 1 month and fully within 6 months. 
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2. Epidemiology 
Drug misuse often goes undetected and many of the quoted figures may be just the 
proverbial tip of the iceberg. Figures below have been taken from results published 
by  the National Advisory Committee on Drugs (NACD) & Drug and Alcohol 
Information and Research Unit (DAIRU) from the 2006/2007 Drug Prevalence 
Survey which was carried out in Ireland and Northern Ireland (and subsequent 
reports of this work published within ‘Drugnet’ – the newsletter of the Alcohol and 
Drug Research Unit - see references). Figures have also been included from the 
European Monitoring Centre for Drugs and Drug Addiction country overview for 
Ireland which can be accessed at: 
 http://www.emcdda.europa.eu/publications/country-overviews/ie#pdu  
 24% of individuals aged 15-64 reported taking an illicit drug during their 
lifetime, with cannabis, ecstasy and cocaine having the highest reported use.  
This had increased from 18% in the previous survey 
 Men reported a higher proportion of drug use than women.  Studies outside 
Ireland report this proportion to be roughly two thirds male to one third 
female (Mayet et al, 2009) 
 The use of the most common illicit drug - cannabis - has not declined in 
Ireland as it has in other parts of Europe, although the number of individuals 
reporting cannabis a main problem drug has decreased 
 Half of all cannabis users had first used the drug before the age of 18. One in 
four cannabis users use the drug on a daily or almost daily basis 
 Ireland is one of the highest countries in Europe for the prevalence of 
cocaine use.  The number of individuals entering treatment programmes for 
cocaine use has increased considerably between 2001-2007 
 Ireland has medium prevalence of European countries for ecstasy use.  
Although rates of use remain relatively stable, the number of individuals 
seeking treatment stating ecstasy is their main problem drug has markedly 
decreased.  Approximately 10 deaths a year are reported from ecstasy use.  
Studies in the UK and Europe indicate that ecstasy use is commonly linked 
with the ‘dance’ scene with 90% of individuals reporting they have used the 
drug at least once (Winstock and Schifano, 2009) 
 Amphetamine use is relatively uncommon in Ireland, although studies from 
the UK indicate that methamphetamine use is becoming more common 
(Winstock and Schifano, 2009) 
 Less than 1% of individuals reported using heroin or crack cocaine over their 
lifetime.  There are approximately 15,000 opiate users in Ireland (figures 
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from 2001).  Almost 90% of drug related deaths in Ireland are related to 
opiate use.  
 Drug use was highest in the 25-34 year age group, followed by the 15-24 
year age group 
 The highest use of sedatives, tranquillisers and antidepressants was found in 
women and older age groups 
 The highest use of volatile substances was in the 15-24 age group 
 The highest use of Opioid substances was in the 35-44 age group  
 63% of individuals entering treatment programmes within Ireland are Opioid 
dependent users, 16% for cannabis and 13% for cocaine 
 36% of individuals entering treatment programmes were aged under 25 
years, and between 70-80% of individuals entering treatment programmes 
are male. 
 Only a low proportion (3% )of individuals reported polydrug use – use of 
more than one illicit substance  
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3. Aetiology 
3.1 Aetiology 
Many factors have been implicated in the initiation of drug abuse but the most 
important factors seem to be the widespread and easy availability of drugs, 
vulnerable personality and adverse social and environmental factors.  Involvement in 
the ‘dance’ or ‘party’ scene emerging since the late 1980’s is also a factor.  
Many individuals who occasionally experiment with drugs do not develop any 
significant problems or dependence. There appears to be a correlation between 
vulnerable personality and developing dependence-related disorders. Poor school 
record, truancy, delinquency, sensation seeking and impulsivity are traits commonly 
associated with drug taking behaviour. 
Disrupted families, divorce, psychiatric disturbances in families, social deprivation, 
unemployment, homelessness and peer pressure within groups are all social 
influences that are linked to an increased tendency to drug use, although cocaine 
powder is the exception to this, as there is also a high degree of use by more 
individuals of higher socio-economic and more affluent status (Seivewright and 
Fung, 2009). Rates of dependence are high in inner city than rural areas. 
 
3.2 Neurobiology of misuse 
Experimentation and occasional use of drugs for recreational purposes is 
widespread and in most cases does not lead to misuse or dependence. Studies 
show that psychoactive drugs act on receptors in the brain to cause their biological 
or psychoactive effects. These effects then act as positive reinforcers for repeated 
drug use in some people. Long term use of drugs leads to adaptive changes in the 
receptors and in nerve terminals leading to unpleasant symptoms on withdrawal of 
the drug. These unpleasant effects then act as a negative reinforcement and thereby 
perpetuate continued use of the drugs.  
For a detailed description of the action of drugs at the receptor level, see Appendix 
K. 
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4. Diagnosis 
Individuals seeking help with substance abuse disorders commonly approach other 
health professionals rather than the GP; for example the community pharmacist, 
nurse, midwife (Department of Health et al, 2007).   
Individuals may present in a variety of ways: 
 Actively requesting help for substance abuse issues or alcohol abuse issues 
(in which case substance misuse disorders should also be considered) 
 Presenting with complications from substance abuse e.g. hepatitis A, B, or C 
infection; HIV infection, thrombophlebitis 
 Presenting with clinical features of withdrawal or Opioid intoxication (see 
below). 
(CKS, 2008) 
A full health assessment should be undertaken where substance abuse is suspected 
due to the high rates of physical and psychiatric morbidity in substance dependence 
(particularly in heroin dependence (Mayet et al, 2009).  This assessment should 
include a full physical examination as well as a mental health assessment to detect 
abnormal general behaviour, disorders of mood (particularly anxiety or low mood), 
delusions or hallucinations, confusion.  
4.1 Clinical Features 
Misuse of drugs and dependence leads to self-neglect which is evident on 
observation. Unkempt and dishevelled appearance, injection scars and wearing long 
sleeves in summer are some informal observations of significance. A disorientated 
person with a glazed look or an extremely drowsy individual is likely to be under the 
influence of drugs. 
The individual is may well understate, or indeed, overstate their drug use for 
secondary gain. History is often unreliable and detailed questions have to be asked 
to establish the pattern of drug use. History of typical drug use during the day, or 
alternatively during a week should be sought. A careful account of the number of 
substances abused, route of ingestion, dangerous practices like injecting in the groin 
and sharing needles, craving, withdrawal symptoms, attempts at detoxification and 
rehabilitation, history of hospital admissions, hepatitis and other complications 
should be recorded. 
4.2 The Mental State Examination 
Appearance and Behaviour 
Drug dependence may lead to varying degrees of self-neglect, which may be 
evident on observation of appearance and behaviour. 
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Cognitive Function 
Cognitive function relates to concentration and memory. Drug dependence may lead 
to varying degrees of cognitive impairment.  
Mood  
Anxiety and depression often coexist with drug misuse. Eye contact and verbal 
interaction is poor in the depressed individual. They may be tearful and appear low 
in mood. An anxious individual is likely to be edgy, irritable and worried about minor 
things. It may be difficult putting an anxious person at ease. Euphoric mood may 
also be encountered. 
Thoughts and Perceptions 
Some drugs are associated with psychotic mental illness. This may be either 
residual or late onset psychotic disorder as described in ICD-10 (WHO, 2007). In 
this disorder the psychotic symptoms occur as a result of drug intake, but persist 
beyond the period during which a direct effect of the substance would be expected. 
Signs such as suspiciousness, pressure of speech, thought blocking, distractibility, 
or the experience of hallucinations would suggest psychosis. 
Insight and Motivation 
Motivation to stop drugs and insight into the drug problem and its far-reaching 
effects are good prognostic factors. Conversely, poor insight and motivation are poor 
prognostic features. 
4.3 Physical Examination 
Physical signs include needle tracks, thrombosis of veins and subcutaneous 
abscesses. 
 Loss of weight (opioids) 
 Chronic respiratory illness (cannabis) 
 Destruction of nasal septum (cocaine) 
 Signs of comorbid conditions such as hepatitis and AIDS 
4.4 Investigations 
Urine testing is generally used in preference to blood tests for the initial assessment 
of illicit drug use, or to confirm treatment compliance, although testing in this 
manner does not confirm drug dependence.  Rarely blood and hair analysis may be 
used. 
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Approximate durations of drug detectability through urine testing are shown below 
(Department of Health et al, 2007). 
 
 
Drug or its metabolite(s)  Duration of 
detectability 
Amphetamines, including methylamphetamine and MDMA  2 days 
Benzodiazepines:  
 Ultra-short-acting (half-life 2h) (e.g. midazolam) 12 hours 
 Short-acting (half-life 2–6h) (e.g. triazolam) 24 hours 
 Intermediate-acting (half-life 6–24h) (e.g. temazepam, 
chlordiazepoxide) 
2–5 days 
 Long-acting (half-life 24h) (e.g. diazepam, nitrazepam) 7 days or more 
Buprenorphine and metabolites  8 days 
Cocaine metabolite  2–3 days 
Methadone (maintenance dosing) (approximate) 7–9 days 
Codeine, dihydrocodeine, morphine, propoxyphene (heroin is 
detected in urine as the metabolite morphine) 
48 hours 
Cannabinoids:  
 Single use 3–4 days 
 Moderate use (three times a week) 5–6 days 
 Heavy use (daily) 20 days 
 Chronic heavy use (more than three times a day) Up to 45 days 
4.5 Clinical Features of Withdrawal 
Signs and symptoms of withdrawal include sweating, tremor, restless, anxious or 
irritable behaviour, runny eyes and nose, extremes of hot and cold, anorexia, 
abdominal cramps, nausea, vomiting, diarrhoea, insomnia, tachycardia, 
hypertension, dilated pupils,  presence of a cough. 
In opiate withdrawal, once the initial symptoms have subsided, these are often 
followed by protracted fatigue and insomnia. Cravings for opioids may last for up to 
6 months or longer. 
Heroin withdrawal symptoms reach their peak 36–72 hours after the last dose and 
subside substantially after 5 days. 
Methadone withdrawal symptoms typically reach their peak 2–4 days after the last 
dose of methadone but may take 10–12 days to resolve.  
Buprenorphine withdrawal symptoms peak within 3–5 days and continue for up to 
several weeks. 
(Department of Health et al, 2007). 
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5. Differential Diagnosis and Comorbidity 
5.1 Differential Diagnosis 
Neuroadaptive changes in brain function and changes in synaptic transmission and 
receptor sensitivity may lead to permanent mental disorders (e.g. residual or late-
onset psychotic disorder).   
There might be other mental disorders in addition to substance abuse or 
dependence. Dual diagnosis (i.e. mental disorders like schizophrenia, PTSD, 
depression etc. and substance abuse) may present difficulties. The presence of pre-
existing mental problems pre-dating drug use may need to be differentiated from the 
mental effects of psychoactive drug abuse. 
Cognitive impairment and behavioural disorders after head injury might present with 
features similar to intoxication and drug abuse.  
Other relevant conditions include: 
 Alcohol related disorders  
 Acute head injury 
 Hypoglycaemia 
 Anxiety conditions 
 Depressive conditions 
 Aggravation or precipitation of another mental condition by substance 
abuse e.g. psychoactive substance-induced psychotic state 
 Organic amnesic syndrome 
 Syndromes involving impairment of memory (e.g. dementia) 
 Mild or Moderate mental retardation 
 Endocrine disorders (e.g. hyperthyroidism) 
The effects of mixed or polydrug use should also be considered. 
(Mayet et al, 2009; Medical Disability Guidelines, 2009) 
5.2 Comorbidity 
Individuals who abuse substances commonly develop co-morbid psychiatric illness 
with prevalence rates for those with Opioid dependent abuse being up to 50% 
(Verthein et al, 2005).  This is increased by concurrent use of alcohol or other drugs 
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especially stimulant classes of substances. 
Other comorbid conditions include 
 Alcohol dependence/abuse 
 Nicotine dependence 
 Anxiety disorders 
 Depressive disorders 
 Hepatitis B and/or C 
 HIV infection 
 Cardiovascular disorders 
 Chronic Pain 
 Endocrine disorders 
 Gastrointestinal disorders 
 Immunologic disorders 
 Mood disorders 
 Neurological disorders 
 Obstetric disorders 
 Personality disorders 
 Psychoses 
 Schizophrenia 
 Antisocial personality disorder 
 Other psychiatric disorders 
 Other substance abuse disorders 
(Mayet et al, 2009; Medical Disability Guidelines, 2009) 
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6. Treatment 
In terms of substance abuse, the greatest proportion of those seeking treatment is 
for Opioid dependence.  This is also likely to be the main problem drug of those 
individuals undergoing incapacity assessment.  Pharmacological treatment options 
below have been shown to be effective for opioid dependence, but no medications 
have been shown in studies to be effective with other classes of drugs such as 
cocaine or cannabis (de Lima, 2002; Seivewright and Fung, 2009).  
Specific treatment options for other classes of illicit drugs are detailed within the 
specific section for each drug contained within the appendices to this protocol. 
6.1 Pharmacological Treatment Options for Opioid Dependence 
The aim of treatment for Opioid dependence can be classified into three goals: 
1. Maintenance treatment of opioid dependence – to achieve reduction 
in harm from intravenous drug use, and to stabilise the individual’s 
lifestyle.  
2. Treatments for withdrawal (detoxification) from opioids – to achieve 
complete abstinence from opiod substance abuse. 
3. Relapse prevention. 
4. Recognition and Management of concomitant use of other drugs of 
depressants.  
Factors influencing the decision as to whether an individual undergoes maintenance 
treatment or detoxification include if the individual is currently taking opioids and the 
degree of dependence they have on opioid substances – an individual may be using 
opioids but may not necessarily be dependent or tolerant of these substances.  The 
individual’s motivation to change their behaviour and degree of commitment will also 
play a part in this decision. 
Treatment setting can vary. Specialist inpatient and outpatient units with psychiatric 
facilities deal with the treatment of drug misuse and dependence. General 
practitioners also manage the day-to-day care of individuals with drug problems.  
6.1.1 Clinical Assessment and Assessment of Dependency 
Clinical assessment with regard to a treatment plan should focus on: 
 Current consumption 
 Typical day and use of substances 
 Drug use history 
 Social circumstances including employment history, criminal activity, 
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relationships; environmental circumstances such as housing 
 Biophysical factors such as episodes of overdose, viral screening, issues 
with routes of administration etc. 
 Psychiatric history 
 Past treatments; past abstinent periods 
 Motivation for change 
Confirmation of dependence and tolerance should also be sought in order to reduce 
the possibility of overdose from methadone in a non tolerant individual. 
6.1.2 Opioid Maintenance Treatment 
This form of treatment involves substituting heroin for a long-acting opioid substance 
which reduces cravings for the drug and avoids intravenous use.  Evidence indicates 
that long term outcomes are better when maintenance therapy is used than 
detoxification programmes. (CKS, 2008). Drugs with slower action are prescribed 
and therefore are less addictive; e.g. methadone is prescribed as a replacement for 
opioid dependence. The rationale behind the replacement approach is as below: 
 It removes the need to obtain "street drugs". 
 It is easier to retain individuals in the programme when they are on 
replacement than those in drug-free programmes. Long-term retention is 
associated with better long-term results. 
 Harmful practices (like sharing injection needles) are controlled or eliminated.  
This type of therapy is usually community based; however inpatient settings may be 
more appropriate should the individual have a complex physical or psychiatric 
history which would make a greater dependence of care necessary.   
Outcomes for maintenance therapy are improved when included as part of a 
package of interventions including psychosocial and pharmacological interventions 
(Mayet et al, 2005).  
Maintenance therapy may be continued in the long term within a community setting, 
or may be used before withdrawal/detoxification treatment with the aim of 
discontinuing all illicit drug use. 
Oral methadone and buprenorphine are usually used for maintenance treatment.  
Evidence indicates there is no difference in effectiveness, however on cost 
effectiveness grounds, methadone is usually selected (NICE, 2007).  Patient 
preference will also play a part as some patients find side effects from one drug 
means they prefer another (e.g. methadone can cause patients to report ‘cloudy’ 
thinking). 
Individuals undergoing maintenance therapy should have a period of supervised 
consumption for at least the first three months, with initial daily contact.  Whilst 
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stable on maintenance therapy they should ideally be reviewed every fortnight or 
monthly with a care plan review undertaken every three months (Department of 
Health et al, 2007). 
6.1.3 Withdrawal/Detoxification 
Detoxification to completely discontinue use of most drugs including opioids can be 
accomplished on an outpatient basis; however for individuals with a history of 
prolonged use of very high doses of hard drugs like opioids, this is best undertaken 
in a hospital setting.   This form of treatment is suitable for highly motivated 
individuals who want to completely stop using any form of opioid substance and 
have stable circumstances which are conducive to maintaining abstinence. 
Some people may choose detoxification without entering maintenance therapy. This 
choice is more suitable for a young user, or people with a low level of drug use or 
those who have used opioids for a short time, or who rarely inject. 
Oral methadone and buprenorphine are the drugs most commonly used, as the 
effectiveness of lofexidine is questionable, especially when used alone (Department 
of Health, 2007).  Where an individual is progressing to detoxification from 
maintenance therapy, the drug they used in that stage should be continued.  Where 
an individual is entering detoxification treatment without having undertaken 
maintenance therapy, buprenorphine is recommended (NCCMH, 2007).  There is 
some evidence to indicate that naltrexone in addition to methadone or 
buprenorphine allows withdrawal to be completed more quickly but this needs to be 
confirmed (Mayet et al, 2009). 
6.1.4 Ultra- rapid withdrawal 
Evidence indicates that ultra-rapid withdrawal has unknown effectiveness in the 
treatment of opioid dependence.  This is primarily due to safety concerns but also 
due to the cost effectiveness of such treatment, and the fact that this method of 
treatment may not encourage individuals to make the life changing positive choices 
necessary to sustain abstinence from substance abuse.  NICE (2007) recommends 
such treatment should only be offered to individuals who have specifically requested 
this form of withdrawal, and fully understand the risks and issues involved with the 
treatment.  NICE also recommends that non-anaesthesia related methods are used 
due to the high mortality rates associated with anaesthesia assisted withdrawal. 
6.1.5 Relapse Prevention 
Once detoxification treatments have been completed, evidence indicates that 
naltrexone is effective in avoiding relapse prevention in the management of opioid 
dependence (NICE, 2007). 
6.2 Psychological treatment for Substance Abuse 
Evidence indicates that psychological therapies alone are not adequate for 
treatment of opiod dependence (Mayet, 2004) but are effective when used alongside 
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pharmacological methods.  However, psychosocial interventions form the basis of 
treatment for individuals who misuse cocaine and other stimulants, cannabis and 
hallucinogens (Department of Health et al, 2007). 
Forms of psychological treatments which can be considered include: 
 Brief Motivational Interventions – short sessions ranging for 5 to 10 minutes 
within existing contacts (e.g. at a GP appointment) should be offered, aimed 
at harm reduction strategies with respect to blood-borne viruses, for example 
on reducing sexual and injection risk (NCCMH, 2007). 
 Cognitive Behavioural Therapy is effective when offered to substance 
abusing individuals who have comorbid anxiety or depressive conditions 
(NCCMH, 2007) 
  A strong evidence base (mainly from the US) exists for Contingency 
Therapy which is based on a reward scheme, e.g. vouchers. This is usually 
provided as part of a structured care plan but is not common within the UK  
(Department of Health et al., 2007) or Ireland. 
 Behavioural couples therapy – where one person within the couple is drug-
free and willing to participate in treatment 
 Family Therapy in the form of self help, structured support groups or formal 
sessions.  Again, although evidence indicates that this is effective, this form 
of therapy is not common in the UK (Department of Health et al, 2007) or 
Ireland. 
 Self help groups such as Narcotics Anonymous and Cocaine Anonymous. 
6.3 Rehabilitation 
The abstinent individual needs to be integrated back into society. Work and social 
contact in sheltered surroundings should be attempted first. Gradual introduction into 
society is then attempted. Unless this can happen, the treatment may fail. 
Rehabilitation is a team effort and involves occupational therapists and social 
workers in addition to the psychiatric team. Social support is indispensable during 
this transition period, and for some time after. Rehabilitation and reintegration 
interventions will depend upon the individual’s motivation, Socio-domestic 
circumstances and physical or mental sequalae. Each of these aspects must be 
rigorously addressed. Flexibility in approach is essential and will be guided by those 
circumstances which dominate in the individual person. 
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7. Prognosis (Main Prognostic Factors) 
Most substance abuse disorders can be considered chronic relapsing conditions 
resulting in severe physical, mental and social consequences (Cami, 2003; Mayet, 
2009)  
In heroin dependent individuals there is a 10-15% mortality at 10 years. The overall 
abstinence in the same group is 50% at 10 years, suggesting a tendency towards 
the eventual avoidance of substance or drug use in the survivors. 
Drug dependence cannot be cured completely; it can only be effectively controlled. 
Relapse is the greatest challenge, and reversion to full-blown dependence is all too 
common. 
The abstinent individual experiences may experience intense craving for the drug, in 
which case there is a tendency to initiate self-administration. This situation usually 
arises after administration of a very small dose of the drug even years after the last 
drug dose. This has been attributed to the "priming effect" of the drug on which the 
individual was dependent. 
Craving and relapses are not the exception, but the rule. Successful treatment 
depends on management of cravings and relapses, in those individual who continue 
usage. 
Contrary to popular belief, craving in abstinent individuals is not produced by the 
absence of the drug, but by its presence. Hence avoidance of exposure to a drug-
related environment may be an important aspect in improving the prognosis6. 
The morbidity of drug misuse is very high. Self-neglect, venous thrombosis, 
abscesses, endocarditis, pneumonia and other infections, HIV, hepatitis, accidental 
overdoses and associated psychiatric morbidity are some of the detrimental 
consequences of drug misuse.  
In addition, there is a high tendency on the part of drug dependent individuals to 
resort to crime to fund their drug habit. 
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8. Information Gathering at the In Person 
Assessment 
The drugs most commonly misused include cocaine, cannabis, heroin, 
benzodiazepines and amphetamines. An increasing evidence of use has been 
reported for drugs like ecstasy and solvents. Polysubstance misuse is also common.  
Many young drug users remain employed and their drug use is viewed as a 
harmless recreational activity by their peer group. Many people do not regard 
occasional use and experimentation with drugs as abnormal. However, drug users in 
employment have a high absenteeism rate and a higher incidence of accidents and 
injuries. Though many who misuse drugs remain employed, the employment rates 
for drug dependent individuals are very low. 
Drug dependence by itself is not covered by the Disability Discrimination Act 1995.  
The disability arising from drug use is highly variable.  
Common ‘street’ or vernacular names for misused substances are detailed in 
Appendix L. 
8.1 Assessing the Claimant  
A mental health assessment must always be done in individuals with a history 
of substance abuse. 
A thorough perusal of all available evidence on file is necessary. It must be borne in 
mind that the effects of drug abuse include aggressive and potentially violent 
behaviour.  
If drug misuse is an unexpected finding then the claimant’s GP should be notified. 
Informed consent from the claimant must be obtained for this.  
History should include pattern, duration, extent, severity and type of drug use. 
Variability over a period of time should be noted. A note must be made of attempts 
at detoxification, if any. A history of current functional impairment(s) should be 
obtained along with an account of a typical day. If the individual leads a haphazard 
existence, an account of a typical week may be more helpful. Adverse socio-
domestic effects and behavioural problems should also be documented. 
If the claimant is in a state of intoxication, consideration should be given to aborting 
the examination, if it is clear that it will not be possible to carry out an appropriate 
assessment. This may be because of threatening or persistent uncooperative 
behaviour. 
8.1.1 Informal Observation 
Informal observation may be of immense help in corroborating the history and any 
documentary evidence. The following observations may be made informally: 
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 General appearance and demeanour  
 Gait, posture and balance 
 Eye contact 
 Involuntary movements and mannerisms 
 State of self care and personal hygiene 
 Facial expressions. 
 Nature of talk and engagement  
8.1.2 Physical Assessment 
This may be appropriate if there are any reported or claimed physical disabilities. 
General physical features to be noted include: 
 General appearance and weight 
 State of self care 
 Smell of breath 
 Gait and posture 
 Skin colour, needle marks and scars. 
8.1.3 Mental State Examination 
It may be difficult to assess the mental state in some cases. It is important to be 
sensitive and non-judgemental in order to be able to gather as much information as 
possible. The following areas need to be assessed: 
 Appearance  
 Behaviour 
 Speech 
 Mood 
 Thoughts and perception 
 Intellect and cognition 
 Insight and motivation. 
Drug use may lead to poor concentration causing inability to read, watch TV and 
enjoy leisure activities. It may be necessary to repeatedly prompt the claimant. 
There may be a history of multiple accidents around the home due to poor 
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concentration and poor memory. 
Daily living activities may be neglected if all time and effort is concentrated on 
obtaining and using drugs. Self-neglect may be evident and the claimant may not 
follow a set daily routine. 
Anxiety, panic or euphoria may result from use of some drugs. Fatigue, lack of 
interest and initiative may lead to a complete disregard of routine tasks. 
Some drugs may cause inappropriate temper outbursts and even physical 
aggression. The ability to communicate and interact with other people may be lost. 
The drug dependent person may prefer solitude or the company of other drug users. 
All information elicited (evidence from file, history, account of typical day, informal 
observation and formal assessment) should be used to assess the overall disability 
and functional impairment. Variability must be fully addressed, and consideration 
given to the severity and duration of the condition so that appropriate prognostic 
advice may be presented in the report.  
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9. Analysis of Effect on Functional Ability 
Eligibility to the Department of Social and Family Affairs various Illness-related 
schemes and Activation Programme, is determined primarily by the degree of 
Ability/Disability and its expected duration. 
The degree of Ability/Disability assessed, using the following Indicators, can be 
depicted on the Ability/Disability Profile illustrated below. 
9.1 Indicators of Ability/Disability  
Normal  
 Normal social functioning 
 Normal mood and concentration 
 Good inter-personal skills 
 Well-motivated to abstain from use 
Mild  
 Recreational drug use only 
 Adequate self-care 
 No loss of interests or hobbies 
 Well groomed with no evidence of self-neglect 
 Intact insight 
 Appropriate behaviour 
Moderate  
 Long history of drug abuse and dependence 
 Multiple failed detoxification attempts 
 Associated mental disorders such as anxiety 
 Intensive input and support from community psychiatric team and social 
services 
 Some evidence of self-neglect 
 Poor insight and motivation 
 Poor social relationships 
 Associated mood disorders 
 Impaired concentration 
Severe  
 Chaotic and disorganised lifestyle 
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 Poly-substance abuse and dangerous injecting habits 
 Compulsive drug seeking behaviour to the exclusion of all other activities 
 Gross self-neglect 
 Grossly impaired social interaction 
 Currently undergoing detoxification or detoxification planned in the near 
future 
 Overdoses or suicide attempts in the last six months 
 Suicidal ideation and low self-esteem 
 Evident gross self-neglect 
 Co-morbidity due to associated severe mental illness 
 Behavioural and/or thought disorders 
 Attends with CPN or care worker 
Profound  
 Drug dependency to a degree, which severely and adversely affects a 
person's behaviour, which severely restricts social functioning and requires 
or is undergoing treatment in a detoxification unit or residential rehabilitation 
unit 
 Mood and/or behaviour are so adversely affected that they are likely to pose 
a real threat or danger to others (work colleagues or members of the public) 
 Severe psychotic behaviour resulting from drug abuse 
 Neurotoxicity, cerebrovascular accident, or other forms of central nervous 
system damage resulting from drug abuse  
In chronic substance abusers displaying self-neglect, there may be an inability to 
maintain adequate levels of nutrition and cleanliness.  Performing essential domestic 
tasks, or coping with day to day transactions and communicating with others 
generally are all likely to be significantly affected. 
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9.2 Ability/Disability Profile 
 
Indicate the degree to which the Claimant’s condition has affected their ability in 
ALL of the following areas.  
 Normal Mild Moderate Severe Profound 
Mental health/Behaviour 
 
 
 
 
 
 
 
 
 
 
Learning/Intelligence 
 
 
 
 
 
 
 
 
 
 
Consciousness/Seizures 
 
 
 
 
 
 
 
 
 
 
Balance/Co-ordination 
 
 
 
 
 
 
 
 
 
 
Vision 
 
 
 
 
 
 
 
 
 
 
Hearing 
 
 
 
 
 
 
 
 
 
 
Speech 
 
 
 
 
 
 
 
 
 
 
Continence 
 
 
 
 
 
 
 
 
 
 
Reaching 
 
 
 
 
 
 
 
 
 
 
Manual dexterity 
 
 
 
 
 
 
 
 
 
 
Lifting/Carrying 
 
 
 
 
 
 
 
 
 
 
Bending/Kneeling/Squatting 
 
 
 
 
 
 
 
 
 
 
Sitting 
 
 
 
 
 
 
 
 
 
 
Standing 
 
 
 
 
 
 
 
 
 
 
Climbing stairs/Ladders 
 
 
 
 
 
 
 
 
 
 
Walking 
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10. Summary of Scheme Criteria  
Scheme eligibility criteria are maintained on the DSP website and are accessible 
from the following links: 
 
 Carer’s Allowance 
http://www.welfare.ie/EN/OperationalGuidelines/Pages/carers_all.aspx 
 
 Carer’s Benefit 
http://www.welfare.ie/EN/OperationalGuidelines/Pages/carers_ben.aspx 
 
 Disability Allowance 
http://www.welfare.ie/EN/OperationalGuidelines/Pages/disall.aspx 
 
 Disablement Benefit 
http://www.welfare.ie/EN/OperationalGuidelines/Pages/oib_disableb.aspx 
 
 Domiciliary Care Allowance 
http://www.welfare.ie/EN/Schemes/IllnessDisabilityAndCaring/Carers/Domicil
iaryCareAllowance/Pages/DomiciliaryCareAllowance.aspx 
 
 Illness Benefit 
http://www.welfare.ie/EN/OperationalGuidelines/Pages/illben.aspx 
 
 Injury Benefit 
http://www.welfare.ie/EN/OperationalGuidelines/Pages/oib_injuryb.aspx 
 
 Invalidity Pension 
http://www.welfare.ie/EN/OperationalGuidelines/Pages/invalidity.aspx 
 
 Respite Care Grant  
http://www.welfare.ie/EN/OperationalGuidelines/Pages/respitegrant.aspx 
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Appendix A - Opioids 
 
These substances can be taken by intravenous injection, subcutaneous injection 
(skin-popping), snorting (sniffing) and inhalation (chasing) and result in strong 
analgesic, euphoriant and anxiolytic effects. Other effects include respiratory 
depression, constipation, reduced appetite and decreased libido. 
Withdrawal syndrome includes intense craving for the drug, restlessness, insomnia, 
muscular pains, runny nose and eyes, sweating, abdominal cramps, diarrhoea, 
vomiting, pilo-erection, dilated pupils, tachycardia and disturbance of temperature 
control. 
Morbidity and mortality is significant in users, with use being described as a chronic 
relapsing disease (Mayet, 2009). 
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Appendix B - Cannabinoids 
Cannabis, commonly known as Marijuana, is a substance derived from the plant 
Cannabis sativa. It contains many psychoactive substances, the most powerful 
being δ-9-tetrahydrocannabinol.  It is used either as the dried vegetative parts in the 
form of marijuana or grass, or as the resin secreted by flowering tops of the female 
plant. Cannabis is commonly smoked with tobacco, but can also be ingested in food 
products.  The effects last from 5-12 hours orally, and 2-4 hours if inhaled. 
Cannabis acts via specific cannabinoid receptors. The endogenous ligand for these 
receptors is anadamide. Cannabis exaggerates the pre-existing mood. It causes 
distortion of perception of time and space, reddening of eyes, dry mouth, 
tachycardia, irritation of respiratory tract and coughing. It also causes anxiety, mild 
paranoid ideation, and at higher doses, can cause toxic confusional states and 
psychosis in clear consciousness. 
Tolerance may develop when high doses are used for long periods, but is rare on 
intermittent use of small doses. The vast majority of those who use cannabis do not 
develop dependence nor do they misuse the drug. 
Withdrawal symptoms from high doses include irritability, nausea, insomnia and 
anorexia. 
(Hall 2009) 
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Appendix C - Sedative Hypnotics  
This is a condition where individuals become dependent on, or abuse, substances 
used for their calming effect (sedatives), sleep-inducing effect (hypnotics), and anti-
anxiety effect (anxiolytics). The most frequently misused drugs in this group are 
benzodiazepines. Other drugs of this group that are misused are chlormethiazole, 
chloral hydrate and very rarely, barbiturates.  
Benzodiazepine misuse is commonly associated with abuse of other substances – 
for example, individuals may take benzodiazepines to alleviate the after effects of 
cocaine use, or to enhance the effect of other drugs. 
Drugs of this class vary in potency and length of effect.  They are usually taken 
orally, although some users have taken substances of this nature intravenously.  
This route of administration is associated with substantially greater mortality and 
morbidity (Welch and Farrell, 2009). 
High levels of psychiatric comorbidity are commonplace in individuals who abuse 
these types of substance. 
Diagnosis 
These drugs act by facilitating brain GABA function. Withdrawal symptoms include 
anxiety, irritability, sweating, tremor, sleep disturbance, altered perception, 
depersonalisation, derealisation, hypersensitivity, abnormal sensations, depression, 
psychosis, seizures and delirium tremens. 
Treatment 
Treatment aims to achieve gradual withdrawal with counselling. Benzodiazepines 
with shorter half-life and high potency, may be replaced by longer-acting drugs like 
diazepam before withdrawal is attempted. 
Barbiturate misuse is rare.  Abrupt withdrawal of barbiturates can be dangerous. In-
patient detoxification is advisable if the dose is high. Replacing the barbiturate by a 
benzodiazepine and then gradual withdrawal may be an option. 
(Medical Disability Guidelines, 2009; Welch and Farrell, 2009) 
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Appendix D - Cocaine  
Cocaine, found in Erythroxylum coca ("Coca") is a stimulant drug, and can cause 
strong dependence in persistent users. 
Dependent on form, it is administered by injection, smoking and sniffing and acts by 
blocking the re-uptake of dopamine in the nucleus accumbens in the midbrain 
dopamine system.  Abuse usually starts with binge or episodic use but dependence 
can develop quickly after only a few months of substance abuse.  Effects last for 30-
50 minutes resulting in individuals taking frequent doses to maintain effects. 
The use of cocaine use leads to excitement, increased energy, euphoria, grandiose 
thinking, impaired judgement and sexual disinhibition. Higher doses can cause 
hallucinations, paranoid ideation and aggressive behaviour. Prolonged use of high 
doses can result in paranoid psychosis with violent behaviour.  
"Crack" cocaine is a form of free base cocaine. It is not soluble in water and is 
smoked. Smoked crack cocaine reaches the brain even faster than injected cocaine 
and produces an immediate "high" or "rush". It is extremely addictive and may lead 
to compulsive cocaine abuse to the exclusion of all other activities. 
Diagnosis 
Physical effects of cocaine use include dilatation of pupils, tachycardia, and 
increased BP. Severe effects include cardiac arrhythmias, myocardial infarction, 
myocarditis, cardiomyopathy, stroke, fits and respiratory arrest. Obstetric 
complications are similar to those of amphetamines.  Sometimes cocaine use leads 
to formication (‘cocaine bugs’) - a sensation as if insects are crawling under the skin. 
Sniffing cocaine can lead to nasal septal perforation. 
Withdrawal symptoms include dysphoria, anhedonia, fatigue and hypersomnolence. 
Severe withdrawal is seen in prolonged use of high doses, and symptoms include 
intense craving, depression and suicidal thoughts. 
Treatment 
Withdrawal followed by cognitive behavioural therapy, relapse prevention and cue 
exposure treatment are preferred lines of management.  There is no evidence that 
any medication therapy is consistently effective in reducing stimulant abuse (de 
Lima et al, 2002). 
(Seivewright and Fung, 2009; Medical Disability Guidelines, 2009) 
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Appendix E - MDMA (Ecstasy) 
The use of 3,4 methylenedioxymethamphetamine (MDMA), popularly known as 
ecstasy, has increased dramatically over the last 10 years, and is closely associated 
with the ‘dance’ or ‘rave’ music scene, and therefore is a substance that tends to be 
abused by a younger population. Alongside the UK, Ireland has one of the highest 
European prevalence rates for ecstasy use at 3.5% lifetime prevalence (European 
Monitoring Centre for Drugs and Drug Addiction, 2008).  
MDMA is a stimulant with mild hallucinogenic effects, which acts by stimulating the 
release of dopamine and 5-hydroxtryptamine (5-HT) in the brain. 
MDMA is usually taken as an oral tablet but may also be taken in capsule or powder 
form.  It is possible to take forms of MDMA intranasally or intravenously. The rising 
popularity of MDMA may be due to the relative inexpensiveness of tablets – which 
can be purchased for less than €10 (European Monitoring Centre for Drugs and 
Drug Addiction, 2008), and continuing to fall still lower.  
Diagnosis 
The effects of MDMA are euphoria, sociability, intimacy, new insights and 
heightened perceptions. Physical effects include loss of appetite, tachycardia, 
sweating and compulsive grinding of teeth. 
Adverse reactions include hyperthermia, which can be a cause of sudden death. 
There have been reports of arrhythmia, hypertensive crisis and intracerebral bleed, 
although pre-existing cardiac disease may have played a role. It has been linked 
with paranoid psychoses and with ‘flashbacks’ weeks or months after ingestion of 
the drug. 
It has the potential to cause long-term neurological damage.  
Treatment 
It is not common for individuals misusing MDMA to seek treatment – less than 1% of 
all treated individuals list MDMA as their primary problem drug (European Monitoring 
Centre for Drugs and Drug Addiction, 2008).  Symptoms which may persist after 
taking MDMA usually resolve within 2-4 weeks following cessation of use, however 
less acute withdrawal symptoms such as mood and sleep disorders may take some 
months to resolve. 
Antidepressant therapy is not recommended until 2-4 weeks of abstinence from 
MDMA (Winstock and Schifano, 2009) 
(European Monitoring Centre for Drugs and Drug Addiction, 2008; Winstock and 
Schifano, 2009) 
 
  
 
 
BearingPoint, Atos Healthcare & DSP Copyright 
EBM Substance Abuse Version: 5.0 FINAL 
                                             Page  36  
 
In association with 
Appendix F - Other Stimulant drugs 
This class of substances includes a wide range of substances.  Amongst the most 
common are: 
 Amphetamine  
 Methamphetamine  
 Methylenedioxypyrovalerone  
 Methylphenidate  
 Phenmetrazine  
 Various appetite suppressants and decongestants 
Cocaine and Methylenedioxymethamphetamine (MDMA – Ecstasy) are also 
considered a stimulant drug, but are discussed in separate sections of these 
appendices.  
The effects of this class of drug are due to their ability to release and block the re-
uptake of dopamine and noradrenaline in the brain, enhancing mood and 
movement.  
These substances can be taken orally, intranasally, smoked, or used intravenously. 
The effects of these substances can be felt within 30 to 40 minutes and last for 4 to 
8 hours, and can result in individuals feeling extreme euphoria (‘high’).  Clinical 
effects include over-talkativeness, over-activity, insomnia, dryness of lips, mouth and 
nose, anorexia, dilated pupils, tachycardia and high blood pressure. Larger doses 
can lead to cardiac arrhythmia, severe hypertension, stroke and rarely circulatory 
collapse. Further higher doses can lead to fits and coma. 
Acute adverse effects include dysphoria, irritability, insomnia, confusion, anxiety and 
panic. Obstetric complications include miscarriage, placental abruption and 
premature delivery. Prolonged use can lead to repetitive stereotyped behaviour and 
paranoid psychosis. Features of the psychosis are persecutory delusions, auditory 
and visual hallucinations and rarely dangerously hostile behaviour. It usually lasts for 
a few weeks, but can in rare cases, persist for months. 
Smoked or injected amphetamine more commonly leads to dependence than does 
the oral form.  
Withdrawal from these forms of drugs can take 2-4 weeks, and is closely linked with 
depressive symptoms.  Other symptoms include anxiety, fatigue, lethargy and 
nightmares. Intense craving and suicidal thoughts are sometimes seen.  
Diagnosis 
Use of stimulant drugs may result in a number of physical symptoms including 
effects on the sympathetic nervous system e.g. raised heart rate and blood 
pressure, dilated pupils, perspiration, nausea or vomiting, psychomotor agitation or 
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retardation.  Individuals may exhibit constant or ‘nervous’ movement.  
The most marked symptoms may not be physical – issues with interpersonal, 
occupational and social functioning are common.  
Marked physical symptoms are not common from withdrawal of stimulant drugs. 
Treatment 
Psychosocial treatments have been found to be effective, but no pharmacological 
treatments have been identified which are effective in cases of psychostimulant 
withdrawal (Shearer and Gowing, 2004) 
(Medical Disability Guidelines 2009; Winstock and Schifano, 2009) 
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Appendix G - Hallucinogens 
This class of substances includes a number of different types of compounds which 
have different effects.  Readily available, drugs in this group include lysergic acid 
diethylamide (LSD), botanical hallucinogens e.g. fungi such as hallucinogenic 
mushrooms. LSD is the most commonly used drug from this group in the UK. 
Hallucinogens exert their effects by acting as partial agonists at brain 5-HT2A 
receptors.  
Diagnosis 
Physical effects are usually not severe and include hypertension, tachycardia and 
dilated pupils. In the presence of pre-existing cardiovascular pathology, 
hypertension can precipitate adverse myocardial and cerebrovascular events. 
Psychological effects include distortion and intensification of sensory perception, 
and confusion between sensory modalities (synaesthesia). The passage of time 
appears to be slowed. Body image may be distorted with a feeling of being outside 
one’s body. This may lead to panic with fears of insanity. There is a risk of suicidal 
and homicidal tendencies. 
Tolerance can occur, but dependence is very rare. 
Treatment 
Anxiolytics are effective in treatment. 
Flashbacks of psychedelic experiences, weeks or months after use of the drug have 
been reported. 
Controversy exists over an association between the use of LSD and long-term 
abnormalities in thinking and behaviour and even schizophrenia; the evidence for 
such an association is very dubious. 
(Abrahm, 2009) 
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Appendix H - Volatile Solvents 
Solvents cover a huge number of substances: Substances commonly abused 
include solvents, adhesives (glue sniffing), petrol, cleaning fluid, aerosols, butane, 
agents used in fire extinguishers, toluene and acetone. 
Clinical effects are similar to alcohol consumption. The nervous system is first 
stimulated and then depressed. The stages of intoxication are - euphoria, blurred 
vision, slurred speech, incoordination, staggering gait, nausea, vomiting and coma. 
There may be frightening visual hallucinations. 
There is no evidence that use of solvents leads to dependence although tolerance 
can occur.  Effects are short lasting – up to 45 minutes- leading to users taking 
repeated doses over a short period of time. (Talk to Frank, 2009) 
Volatile solvents probably act by increasing brain GABA function and by increasing 
the fluidity of neuronal cell membranes. 
Sudden death may occur. The main causes are cardiac arrhythmias and respiratory 
depression. Other causes of sudden death include trauma, asphyxiation when using 
plastic bags over the head, and inhalation of stomach contents. 
Chronic users display evidence of neurotoxicity and peripheral neuropathy. There 
may be evidence of impaired cerebellar function, encephalitis and dementia. Other 
vital organs may also suffer damage. 
 
(Ives, 2009) 
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Appendix I - Dissociative Substances  
Substances in this class of psychoactive drugs include the following:  
 Dextromethorphan (DXM; Robitussin, Delsym, Triaminic, Coricidin, etc; 
"Dex", "Robo", "Triple CCC", "Cough Syrup")  
 Ketamine (K; Ketalar, Ketaset, Ketanest; "Ket", "Kit Kat", "Special-K", 
"Vitamin K", "Jet Fuel", "Horse Tranquilizer")  
 Nitrous Oxide (N2O; "Nozz", "Laughing Gas", "Whippets")  
 Phencyclidine (PCP; Sernyl; "Angel Dust", "Rocket Fuel", "Killer Weed", 
"Super Grass") 
These types of drugs have been generally developed as dissociative anaesthetic 
agents, but their use has been associated with adverse reactions like delirium and 
hallucinations.  These reactions are different from other classes of hallucinogens 
such as LSD. 
Dextromethorphan 
This is an ingredient commonly found in cough medicine and is classified as a 
dissociative psychedelic drug.  Used at much higher than recommended doses can 
result in effects that are similar to those of ketamine and phencyclidine. 
Although preparations containing this drug are available as over the counter 
medicine, it is normally only sold with a pharmacist’s approval. 
Ketamine 
This drug is similar to PCP but with a shorter half life.  It is classed within the UK as 
a Class C drug (Winstock and Schifano, 2009) and as a prescription only drug in 
Ireland.  Its use is common across a number of areas of medicine including major 
trauma and battle zones, but it is also common in veterinary practice which may 
contribute to its availability.   
The street value of this drug is relatively low which is resulting in an increase in 
availability and popularity. Typically the substance is taken intranasally although it 
can be injected or taken orally. 
Ketamine is increasingly linked to the “rave” or “dance” scene with a prevalence of 
about 20% of clubbers (Winstock and Schifano, 2009).  The effects generally last 1-
2 hours so users of this substance may take repeated doses over a short period of 
time. 
Adverse effects are commonly chest pain, palpitations, tachycardia, nausea, 
vomiting, ataxia, temporary paralysis or difficulty with speech, derealisation or 
depersonalisation.  When taken in overdose this drug is relatively safe although 
more harmful and sometimes fatal effects can result when Ketamine is combined 
with CSN depressants.   More long term effects include urinary tract problems.  
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Nitrous Oxide 
Nitrous oxide (N2O) is a colourless, gaseous dissociative drug that can cause 
analgesia, depersonalization, derealisation, dizziness, euphoria and sometimes 
hallucinations.  Used as an inhalant, illicit use of the substance is usually from the 
propellant used in compressed gas containers in a balloon or plastic bag. 
Nitrous oxide is short-lived with the effects dissipating in less than a minute.  
Dependency does not usually result from the use of nitrous oxide. 
Phencyclidine 
This drug is not commonly used within the UK or Ireland.  The drug can be ingested, 
smoked or injected.  It acts at the N-methyl-D-aspartate (NMDA) receptors in the 
brain.  At small doses it produces ‘drunkenness’, analgesia of fingers and toes and 
anaesthesia. Intoxication is prolonged and marked by agitation, depressed 
consciousness, psychotic features, aggression, high BP and nystagmus. With higher 
doses there is a likelihood of ataxia, muscle rigidity and absence of response to 
stimuli with eyes wide open. 
With serious overdoses, an adrenergic crisis with its attendant complications may 
occur. Death may result from cardiovascular or cerebrovascular events or from 
respiratory failure. There is a risk of suicide as well. 
Chronic use leads to aggression with amnesia. Tolerance and dependence can 
occur, but withdrawal symptoms are very rare indeed. 
Treatment of intoxication depends on the symptoms. Haloperidol and/or diazepam 
may be given. Respiratory and cardiac manifestations are dealt with accordingly. 
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Appendix J - Other Substances 
Gamma Hydroxy Butyrate (GHB) 
This drug is in increasing use, particularly with respect to the ‘dance’ scene. 
GHB was originally developed as a general anaesthetic, but has also been used as 
treatment for insomnia, clinical depression, narcolepsy, and alcoholism, and as a 
performance enhancing substance in athletics.  GHB has also been linked to use as 
a ‘date rape’ drug. 
A colourless and odourless liquid or powder with a salty taste, GHB results in 
euphoria, increased enjoyment of movement and music, increased libido, increased 
sociability and intoxication. Adverse effects include nausea, dizziness, drowsiness, 
agitation, visual disturbances, depressed breathing, amnesia, collapse, 
unconsciousness, and death.  There is a significant risk of overdose, especially if 
large doses have been taken alongside alcohol (Winstock and Schifano, 2009). 
The effects of GHB can last from 1.5 to 3 hours or even longer if large doses have 
been consumed or if it is mixed with alcohol. 
There are reports of dependence and withdrawal syndromes developing in 
individuals who have used this substance (Winstock and Schifano, 2009). 
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Appendix K - Neurobiology of drug misuse and 
dependence 
The target for action of most psychoactive drugs seems to be the nucleus 
accumbens in the midbrain dopamine system. The ingestion of certain drugs 
increases the release of dopamine in the nucleus accumbens and leads to feelings 
of euphoria and reduction in anxiety. Dopamine pathways also form a reward 
system, and drugs acting on it act as positive reinforcing agents, heightening the 
feelings of euphoria, and thereby increasing the propensity for misuse.  
Learning and conditioning factors after prolonged misuse of drugs are important in 
the development of tolerance, withdrawal syndrome and dependence.  
Neuroadaptive changes and altered brain function are responsible for phenomena 
such as anhedonia, craving and dysphoria resulting from discontinuation of drugs 
after long-term dependence. 
Other drugs act by enhancing the brain GABA function. On long-term use of these 
drugs, there are changes in the sensitivity of the GABA and benzodiazepine 
receptors. This down-regulation of receptor sensitivity could be responsible for 
development of tolerance and the need for higher doses to produce the same 
effects. Adaptive changes in the receptors tend to persist, and on abrupt 
discontinuation of drugs, (e.g. anxiolytics) there is sharp drop in GABA activity 
leading to anxiety, insomnia and seizures.  
This common pathway of brain action may be responsible for cross-tolerance 
between anxiolytics, alcohol and hypnotics, and it also helps the clinician to treat 
alcohol withdrawal with a benzodiazepine. 
Cannabis exerts its effects via specific cannabinoid receptors in the brain. The 
receptors may be responsible for the effects of endogenous cannabinoids, cannabis, 
certain other drugs and even chocolate cravings. 
Opioids, in addition to acting on opioid receptors, also act on noradrenaline cell 
bodies in the brain stem. Adaptive changes occur in opioid receptors and the firing 
of noradrenaline cell bodies is reduced. If opioids are suddenly withdrawn, the rate 
of firing of noradrenaline cells increases, resulting in sweating, tachycardia, 
hypertension and anxiety. Hence alpha-2 receptor antagonists like clonidine and 
lofexidine are used in the management of opioid withdrawal. 
Positive reinforcing actions of drugs promote drug use and similarly withdrawal 
effects play an important part by negative reinforcement, i.e. dependent individuals 
try to avoid unpleasant withdrawal effects by continued use of drugs. 
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Appendix L - Vernacular Names for Commonly 
Misused Substances 
L.1 Opioids 
Substances that individuals may misuse in this class include: 
 Buprenorphine (Temgesic)  
 Codeine  
 Diacetylmorphine (Heroin; "Smack", "Dope", "Tar") 
 Dihydrocodeine (DHC) 
 Pethidine  
 Methadone  
 Morphine (MS-Contin, MS-IR; "Morpha", "Emma") 
 Opium (from Papaver somniferum ("Opium Poppy")) 
L.2 Cocaine 
Cocaine is commonly known as "Coke", "Crack", "Blow" or "Snow". 
L.3 Other Stimulant Drugs 
 ‘Street’ names for other classes of stimulant drugs include: 
 Amphetamine (Adderall, Dexedrine; "Speed")  
 Methamphetamine (Desoxyn; "Meth", "Crank", "Crystal", "Tweak", "Glass")  
 Methylenedioxypyrovalerone (MDPV; "Sonic", "Magic")  
 Methylphenidate (Ritalin, Focalin, Concerta)  
 Phenmetrazine (Preludin; "Prellies", "Preludes") 
L.4 Dissociative Substances 
Vernacular names for these classes of psychoactive drugs include the following:  
 Dextromethorphan (DXM; Robitussin, Delsym, Triaminic, Coricidin, etc; 
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"Dex", "Robo", "Triple CCC", "Cough Syrup")  
 Ketamine (K; Ketalar, Ketaset, Ketanest; "Ket", "Kit Kat", "Special-K", 
"Vitamin K", "Jet Fuel", "Horse Tranquilizer")  
 Nitrous Oxide (N2O; "Nozz", "Laughing Gas", "Whippets")  
 Phencyclidine (PCP; Sernyl; "Angel Dust", "Rocket Fuel", "Killer Weed", 
"Super Grass") 
L.5 Gamma Hydroxy Butyrate (GHB) 
GHB is commonly known as G; Xyrem; "Liquid Ecstasy" or "Fantasy”  
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